'Musculoskeletal DTx' EverX Kicks Off US Entry with US Expo and Conference Roadshow

EverEx, a digital healthcare company specializing in musculoskeletal disorders, announced on the 17th that it showcased the competitiveness and technological capabilities of its solution ‘MORA’ to medical professionals and healthcare industry stakeholders by consecutively participating in U.S. digital healthcare exhibitions and conferences such as 'DTx East' and 'HLTH 2023.'

EverEx announced on the 17th that it showcased 'EverEx Rehab' at the California Physical Therapists Association Annual Conference (CPTA) held in California, USA, on the 7th and 8th. Yoon Chan, CEO of EverEx (third from the left), and other officials are posing for a commemorative photo.
[Photo by EverEx]

EverEx participated in ‘DTx East 2023,’ the world’s largest digital therapeutics (DTx) event held in Boston, USA, from the 26th to 28th of last month (local time), where it was selected as the representative DTx company in the musculoskeletal field and presented at the ‘Start-Up Showcase,’ held for the first time at the conference. During the ‘Shark Tank Pitches’ session aimed at multinational pharmaceutical companies and venture capitalists (VCs), EverEx presented the prospects of multidisciplinary DTx in the musculoskeletal field and its AI-based MORA platform, garnering positive evaluations from investors and attendees on site.

Following this, earlier this month, EverEx attended U.S. conferences to introduce ‘EverEx Rehab,’ the U.S. version of the MORA platform, to leading medical experts, developing a business model capable of monetization in the U.S. market and boldly challenging overseas expansion. On the 7th and 8th, the company participated in the California Physical Therapy Association (CPTA) Annual Conference held in California, USA, and from the 8th to 11th, it took part in ‘HLTH 2023,’ a digital healthcare conference held in Las Vegas, USA, focusing on promoting EverEx Rehab, an FDA-registered product eligible for U.S. Remote Therapeutic Monitoring (RTM) reimbursement, and raising awareness of the company and its products.

EverEx plans to leverage the environment in the U.S., where RTM reimbursement was introduced last year, allowing insurance claims through RTM CPT codes from Medicare, public insurance, and private insurance, to expand monetization and commercialization. Notably, EverEx Rehab was developed as a U.S. business model and was registered as a Class II medical device with the FDA in July. It offers objective monitoring services based on the AI-powered extensive rehabilitation and exercise curriculum and pose-estimation technology, which are considered key strengths of the MORA platform currently used in Korea.

Yoon Chan, CEO of EverEx, stated, “EverEx Rehab has secured real-world use cases in the U.S. market, gaining recognition for its innovation and technological capabilities,” adding, “The positive evaluations received at conferences and other activities represent a meaningful opportunity signaling a green light for our U.S. expansion.” He further commented, “We expect to establish leadership within the emerging blue ocean of the RTM reimbursement system in the U.S., leveraging EverEx’s technological strengths.”